Search

Displaying results 2891 - 2900 of 7186 in total
  1. Drug

    Flosequinan

    go.drugbank.com/drugs/DB13228
    ApprovedWithdrawn

    Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]

  2. Drug

    Simoctocog alfa

    go.drugbank.com/drugs/DB09108
    Approved

    As patients with haemophilia A are predisposed to episodes of recurrent bleeding [L1115], simoctocog alfa can be administered for the treatment or prevention of bleeding such as prior to surgical procedures … The harvested product is concentrated and purified by a series of chromatography steps.

  3. Drug

    Peach

    go.drugbank.com/drugs/DB10552
    Approved

    Peach allergenic extract is used in allergenic testing.

  4. Drug

    Alprenolol

    go.drugbank.com/drugs/DB00866
    ApprovedWithdrawn

    Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties.

    Synonyms: 1-(o-Allylphenoxy)-3-(isopropylamino)-2-propanol
  5. Drug

    Urethane

    go.drugbank.com/drugs/DB04827
    ApprovedWithdrawn

    Urethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.

  6. Drug

    Raxibacumab

    go.drugbank.com/drugs/DB08902
    ApprovedInvestigational

    Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.

  7. Drug

    FT516

    go.drugbank.com/drugs/DB15732
    Investigational

    FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). … This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation.

  8. Drug

    Teniposide

    go.drugbank.com/drugs/DB00444
    ApprovedInvestigational

    Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle. … Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding.

    Synonyms: 4'-demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside)
  9. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    Tisotumab vedotin is the first TF-directed ADC [A238914] that works by binding to TFs expressed on solid tumours. … Tisotumab vedotin targets TF-expressing cells to deliver MMAE to induce direct cytotoxicity and bystander killing of neighboring cells.

    Synonyms: HuMax-TF-ADC
  10. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. … It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986]